Some of the established therapeutic targets that were highly ranked in our B-ALL target repurposing analysis include TNF-alpha [62,63,64], IL-6 [65,66], TP53 [67,68], AKT1 [69], and BCL2 [70]. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.